Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 159

1.

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.

Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F.

PLoS One. 2016 May 25;11(5):e0156221. doi: 10.1371/journal.pone.0156221. eCollection 2016.

2.

Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Bossi P, Cortinovis D, Cossu Rocca M, Roila F, Seminara P, Fabi A, Canova S, Verri E, Fatigoni S, Iannace A, Macchi F, Ripamonti C.

J Altern Complement Med. 2016 Apr 26. [Epub ahead of print]

PMID:
27115042
3.

Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation.

Maselli A, Capoccia S, Pugliese P, Raggi C, Cirulli F, Fabi A, Malorni W, Pierdominici M, Ortona E.

Oncoimmunology. 2015 Aug 12;5(2):e1074375. eCollection 2016 Feb.

4.

AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.

Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E.

Neuro Oncol. 2016 Mar 6. pii: now035. [Epub ahead of print]

PMID:
26951379
5.

Spine surgery in patients with metastatic breast cancer. A retrospective analysis.

Telera S, Caroli F, Raus L, Pompili A, Carosi MA, Di Santo M, Sperduti I, Carapella CM, Fabi A.

World Neurosurg. 2016 Feb 20. pii: S1878-8750(16)00310-7. doi: 10.1016/j.wneu.2016.02.065. [Epub ahead of print]

PMID:
26906893
6.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.

Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nisticò C, Caterino M, De Vita R, Mottolese M, Iacorossi L, Cognetti F.

Drug Des Devel Ther. 2015 Nov 20;9:6177-83. doi: 10.2147/DDDT.S89575. eCollection 2015.

7.

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.

Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M.

Oncotarget. 2015 Dec 15;6(40):42773-80. doi: 10.18632/oncotarget.6001.

8.

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.

J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.

PMID:
26423801
9.

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L.

PLoS One. 2015 Sep 25;10(9):e0139650. doi: 10.1371/journal.pone.0139650. eCollection 2015. No abstract available.

10.

Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.

Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A.

Neuroradiology. 2015 Dec;57(12):1269-80. doi: 10.1007/s00234-015-1582-9. Epub 2015 Sep 12.

PMID:
26364181
11.

Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study.

Maschio M, Dinapoli L, Fabi A, Giannarelli D, Cantelmi T.

J Neurooncol. 2015 Nov;125(2):419-26. doi: 10.1007/s11060-015-1933-8. Epub 2015 Sep 11.

PMID:
26362046
12.

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.

Villani V, Casini B, Pace A, Prosperini L, Carapella CM, Vidiri A, Fabi A, Carosi M.

Dis Markers. 2015;2015:604719. doi: 10.1155/2015/604719. Epub 2015 Aug 11.

13.

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L.

PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0139650.

14.

The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.

Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, Schillaci O, Floris R, Marzi S, Fabi A, Pace A.

Anticancer Res. 2015 Sep;35(9):5117-22.

PMID:
26254416
15.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.

PMID:
25675124
16.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.

17.

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.

Sanna G, Fabi A, Crivellari D, Saracchini S, Battelli N, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L.

Tumori. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904.

PMID:
25296593
18.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

19.

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.

Fabi A, Mottolese M, Segatto O.

J Mol Med (Berl). 2014 Jul;92(7):681-95. doi: 10.1007/s00109-014-1169-7. Epub 2014 May 28. Review.

PMID:
24861025
20.

Weight of epilepsy in brain tumor patients.

Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, Pompili A, Carapella CM, Cantelmi T.

J Neurooncol. 2014 Jun;118(2):385-93. doi: 10.1007/s11060-014-1449-7. Epub 2014 May 1.

PMID:
24789254
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk